PanGenetics B.V., a therapeutic antibody development company, focuses on the development of monoclonal antibodies for the treatment of immune mediated diseases, cancer, and pain. The company develops a portfolio of antibody drugs through in-licensing model. Its products pipeline includes PG102-Prototype, an original chimeric anti-CD40 antibody; PG102, a CD40 antagonist; PG130, an undisclosed therapeutic antibody; and PG140, an antagonist of CD86. PanGenetics B.V. was formerly known as Tanox Pharma B.V. The company was founded in 1995 and is headquartered in Utrecht, the Netherlands with an additional office in Royston, nr Cambridge.
| Website | http://www.pangenetics.com |
| Revenue | $7.2 million |
| Employees | 1 (0 on RocketReach) |
| Founded | 1995 |
| Phone | +31 30 253 7911 |
| Technologies |
JavaScript
,
HTML
,
Google Analytics
+7 more
(view full list)
|
| Industry | Pharmaceutical Manufacturing, Biotechnology, Pharmaceutical, Drug Delivery, Pharmaceuticals, Health Care, Drug Discovery, Healthcare |
| Web Rank | 27 Million |
| Keywords | Antibody Drugs, Monoclonal Antibodies, Drug Development, Therapeutics, Cancer Treatment, Immunology, Antibody Engineering, Immunotherapy, Pain Treatment, Pharmaceutical Research, Oncology, Clinical Development, Biotechnology, Pharmaceutical, Biopharma, In Licensing, Precision Medicine |
| Competitors | Novo Nordisk, Amgen, Regeneron, Invitae, Actavis plc (now Allergan), MediSieve, Histogenics Corporation, CELL MEDICA LIMITED, Medivet Biologics LLC, Haplogen +41 more (view full list) |
| SIC | SIC Code 283 Companies, SIC Code 28 Companies |
| NAICS | NAICS Code 325 Companies, NAICS Code 3254 Companies, NAICS Code 32 Companies |
Looking for a particular PanGenetics BV employee's phone or email?
PanGenetics BV Questions
The PanGenetics BV annual revenue was $7.2 million in 2026.
The NAICS codes for PanGenetics BV are [325, 3254, 32].
The SIC codes for PanGenetics BV are [283, 28].
Related Companies
